PATENT CLAIM ANALYSIS

Application Number: 16180641
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-05
Patent Classification: ["514", "254110"]

Abstract:
The present invention relates to a method of treating schizophrenia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a selective D3 antagonist, wherein said subject has at least one negative symptom (NS) among the following core negative symptoms in PANSS: Blunted Affect (N1), Emotional Withdrawal (N2), Poor Rapport (N3), Passive withdrawal (N4), and Lack of Spontaneity (N6); with moderate or higher severity. Methods for improving the probability of success and/or the effect of a treatment of schizophrenia in a subject in need thereof are also described.

Claim (Index 12):
The method of  claim 11 , wherein said selective D3 antagonist is N-(3-{4[-4-(8-oxo-8H-[1,3 3 ]dioxolo[4,5-g]chromen-7-yl)-butyl]-piperazin-1-yl}-phenyl)-methanesulfonamide of the following formula 1 or a pharmaceutically acceptable salt thereof:

Metadata:
- Claim Count in Document: 20.0
- Percentile: 98.0
- Lexical Diversity: 1.57333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13754769', '15101874', '10525021', '11175832', '11918287']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7527767780307227
- 35 USC 102 Novelty (BERT): 0.5033303344308395
- Combined Prediction Score: 0.7278321336707344
- Mean Citation Score: 229.297148
- Max Citation Score: 234.91684
- Similarity Product: 157.79890640991212

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test